www.responsebio.com
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.
News
-
30/09/11
Response Biomedical restates accounts for improper revenue, costs -
02/09/11
Roche Diagnostics ends Response Biomedical agreement on lack of FDA approval -
12/03/10
Response Biomedical losses narrow as diagnostic tests sales gather pace
Recent Sector News
-

Dow suffers on Greece fears, Hewlett-Packard in focus
U.S. equity markets fell Wednesday afternoon on concerns that Greece could exit the euro as the region’s gather for an informal meeting.
-

Dow points lower ahead of eurozone meeting, Facebook, Dell in focus
U.S. equity markets looked set to open lower Wednesday morning ahead of a meeting of European Union leaders amid continued worries over the eurozone debt crisis.
-

Q1 gold demand underpinned by China, Central Banks and ETFs
Global gold demand in the first quarter of 2012 was 1,097.6 tonnes, down 5 percent from the high demand levels seen a year earlier, according to the World Gold Council.
-

Medgenics cleared by FDA to begin Phase IIb clinical trials for EPODURE; shares up
Biopharmaceutical company Medgenics (LON:MEDG, AMEX:MDGN) achieved a major milestone today - with clearance to begin a phase IIb trial of EPODURE to treat anaemia in kidney failure patients.
-

Facebook boosts public offering by 25%
Social network site Facebook Wednesday increased the size of its initial public offering by almost 25 per cent as it could raise as much as $16 billion on strong investor demand for its market debut.
-

Snipp plans ambitious growth as mobile marketing takes off
Mobile marketing company Snipp (CVE:SPN) (TSX.V:SPN), which recently listed on the TSX Venture Exchange, is now seeking a listing on the OTC exchange as it continues to grow in a space that is seeing more and more traction from companies looking to boost their marketing efforts.
What do others think of Response Biomedical Corp
Investors interested in Response Biomedical Corp recently viewed
-
Medgenics (AIM: MEDG) Developing "Biopump" technology for the treatment of chronic diseases -
Amphion Innovations (LON: AMP) Amphion builds shareholder value in the medical and technology sectors -
e-Therapeutics plc (AIM: ETX) Systems Biology Drug Discovery -
ImmunoCellular Therapeutics (OTCBB: IMUC) . -
Silence Therapeutics (AIM: SLN) A leader in RNAi therapeutics


















